Piperlongumine downregulates the expression of HER family in breast cancer cells

Biochemical and Biophysical Research Communications

Volumn 486, Issue 4, 2017, Pages 1083-1089

  Jin, Hyeon Ok ^a   Park, Jin Ah ^a   Kim, Hyun Ah ^b   Chang, Yoon Hwan ^b   Hong, Young Jun ^b   Park, In Chul ^a   Lee, Jin Kyung ^a,b  

^a Korea Institute of Radiation and Medical Science   (South Korea)

^b Korea Cancer Center Hospital   (South Korea)

Author keywords

Breast cancer; HER1; HER2; HER3; Piperlongumine; Reactive oxygen species

Indexed keywords

ACETYLCYSTEINE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; NATURAL PRODUCT; PIPERLONGUMINE; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; 1,3 DIOXOLANE DERIVATIVE; PIPERLONGUMININE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER CELL; CANCER CHEMOTHERAPY; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; DOWN REGULATION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; APOPTOSIS; BIOSYNTHESIS; BREAST NEOPLASMS; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; MCF-7 CELL LINE; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DIOXOLANES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ERBB RECEPTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; REACTIVE OXYGEN SPECIES;

EID: 85017130778     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2017.03.166     Document Type: Article

References (22)

1. [1] Yarden, Y., Sliwkowski, M.X., Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2 (2001), 127–137.
2. [2] Holbro, T., Hynes, N.E., ErbB receptors: directing key signaling networks throughout life. Annu. Rev. Pharmacol. Toxicol. 44 (2004), 195–217.
3. [3] Tsutsui, S., Ohno, S., Murakami, S., Hachitanda, Y., Oda, S., Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer. Breast Cancer Res. Treat. 71 (2002), 67–75.
4. [4] Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A., McGuire, W.L., Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987), 177–182.
5. [5] Arteaga, C.L., Sliwkowski, M.X., Osborne, C.K., Perez, E.A., Puglisi, F., Gianni, L., Treatment of HER2-positive breast cancer: current status and future perspectives. Nat. Rev. Clin. Oncol. 9 (2011), 16–32.
6. [6] Garrett, J.T., Arteaga, C.L., Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications. Cancer Biol. Ther. 11 (2011), 793–800.
7. [7] Raj, L., Ide, T., Gurkar, A.U., Foley, M., Schenone, M., Li, X., Tolliday, N.J., Golub, T.R., Carr, S.A., Shamji, A.F., Stern, A.M., Mandinova, A., Schreiber, S.L., Lee, S.W., Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 475 (2011), 231–234.
8. [8] Bezerra, D.P., Pessoa, C., Moraes, M.O., Alencar, N.M., Mesquita, R.O., Lima, M.W., Alves, A.P., Pessoa, O.D., Chaves, J.H., Silveira, E.R., Costa-Lotufo, L.V., In vivo growth inhibition of sarcoma 180 by piperlonguminine, an alkaloid amide from the Piper species. J. Appl. Toxicol. 28 (2008), 599–607.
9. [9] Nogueira, V., Hay, N., Molecular pathways: reactive oxygen species homeostasis in cancer cells and implications for cancer therapy. Clin. Cancer Res. 19 (2013), 4309–4314.
10. [10] Pelicano, H., Carney, D., Huang, P., ROS stress in cancer cells and therapeutic implications. Drug Resist Updat 7 (2004), 97–110.
11. [11] Han, S.S., Son, D.J., Yun, H., Kamberos, N.L., Janz, S., Piperlongumine inhibits proliferation and survival of Burkitt lymphoma in vitro. Leuk. Res. 37 (2013), 146–154.
12. [12] Golovine, K.V., Makhov, P.B., Teper, E., Kutikov, A., Canter, D., Uzzo, R.G., Kolenko, V.M., Piperlongumine induces rapid depletion of the androgen receptor in human prostate cancer cells. Prostate 73 (2013), 23–30.
13. [13] Makhov, P., Golovine, K., Teper, E., Kutikov, A., Mehrazin, R., Corcoran, A., Tulin, A., Uzzo, R.G., Kolenko, V.M., Piperlongumine promotes autophagy via inhibition of Akt/mTOR signalling and mediates cancer cell death. Br. J. Cancer 110 (2014), 899–907.
14. [14] Wang, Y., Wang, J.W., Xiao, X., Shan, Y., Xue, B., Jiang, G., He, Q., Chen, J., Xu, H.G., Zhao, R.X., Werle, K.D., Cui, R., Liang, J., Li, Y.L., Xu, Z.X., Piperlongumine induces autophagy by targeting p38 signaling. Cell Death Dis., 4, 2013, e824.
15. [15] Asrani, K., Keri, R.A., Galisteo, R., Brown, S.A., Morgan, S.J., Ghosh, A., Tran, N.L., Winkles, J.A., The HER2- and heregulin beta1 (HRG)-inducible TNFR superfamily member Fn14 promotes HRG-driven breast cancer cell migration, invasion, and MMP9 expression. Mol. Cancer Res. 11 (2013), 393–404.
16. [16] Zhang, D., Pal, A., Bornmann, W.G., Yamasaki, F., Esteva, F.J., Hortobagyi, G.N., Bartholomeusz, C., Ueno, N.T., Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells. Mol. Cancer Ther. 7 (2008), 1846–1850.
17. [17] Takagi, S., Banno, H., Hayashi, A., Tamura, T., Ishikawa, T., Ohta, Y., HER2 and HER3 cooperatively regulate cancer cell growth and determine sensitivity to the novel investigational EGFR/HER2 kinase inhibitor TAK-285. Oncoscience 1 (2014), 196–204.
18. [18] Adams, D.J., Dai, M., Pellegrino, G., Wagner, B.K., Stern, A.M., Shamji, A.F., Schreiber, S.L., Synthesis, cellular evaluation, and mechanism of action of piperlongumine analogs. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 15115–15120.
19. [19] Lee-Hoeflich, S.T., Crocker, L., Yao, E., Pham, T., Munroe, X., Hoeflich, K.P., Sliwkowski, M.X., Stern, H.M., A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res. 68 (2008), 5878–5887.
20. [20] Jin, H.O., Lee, Y.H., Park, J.A., Lee, H.N., Kim, J.H., Kim, J.Y., Kim, B., Hong, S.E., Kim, H.A., Kim, E.K., Noh, W.C., Kim, J.I., Chang, Y.H., Hong, S.I., Hong, Y.J., Park, I.C., Lee, J.K., Piperlongumine induces cell death through ROS-mediated CHOP activation and potentiates TRAIL-induced cell death in breast cancer cells. J. Cancer Res. Clin. Oncol. 140 (2014), 2039–2046.
21. [21] Nowsheen, S., Cooper, T., Bonner, J.A., LoBuglio, A.F., Yang, E.S., HER2 overexpression renders human breast cancers sensitive to PARP inhibition independently of any defect in homologous recombination DNA repair. Cancer Res. 72 (2012), 4796–4806.
22. [22] Smith, V., Hobbs, S., Court, W., Eccles, S., Workman, P., Kelland, L.R., ErbB2 overexpression in an ovarian cancer cell line confers sensitivity to the HSP90 inhibitor geldanamycin. Anticancer Res. 22 (2002), 1993–1999.